menu

Medical Industry Feature: A Closer Look at the RAS Wild-Type CRC Treatment Landscape

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

A Closer Look at the RAS Wild-Type CRC Treatment Landscape

A Closer Look at the RAS Wild-Type CRC Treatment Landscape
RestartResume

What is the evolving role of immune checkpoint inhibitors and of the rechallenge with anti-EGFR in the treatment of RAS wild-type metastatic colorectal cancer?

  • Overview

    This program is intended for healthcare professionals only and is supported by an independent educational grant from the Healthcare business of Merck KGaA, Darmstadt, Germany.

    Here to break down the treatment of RAS wild-type colorectal cancer along the continuum of care is Professor Claus-Henning Köhne.

    GBPMLR/NONO/1019/0043c

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 3/30/20